{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:50:00Z","timestamp":1772250600330,"version":"3.50.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["1033"],"award-info":[{"award-number":["1033"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine whether polymorphisms of SLC22A1 and SLCO1B3 genes could predict imatinib (IM) response and chronic myeloid leukemia (CML) risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We genotyped SLC22A1 (c.480G\u2005&amp;gt;\u2005C, c.1222A\u2005&amp;gt;\u2005G) and SLCO1B3 (c.334T\u2005&amp;gt;\u2005G, c.699G\u2005&amp;gt;\u2005A) polymorphisms in 132 patients with CML and 109 sex- and age-matched healthy subjects. The patients were evaluated for cytogenetic response by standard chromosome banding analysis (CBA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Polymorphism analysis showed significant increased risk of IM resistance for SLC22A1c.1222AG (P\u2005=\u2005.03; OR\u2005=\u20052.2), SLCO1B3c.334TT\/TG genotypes (P\u2005=\u2005.007; OR\u2005=\u20054.37) and 334T allele (P\u2005=\u2005.03; OR\u2005=\u20052.86). The double combinations of SLC22A1c.480CC and c.1222AG polymorphisms with SLCO1B3c.334TT\/TG were significantly associated with complete cytogenetic response (CCyR) (P\u2005&amp;lt;.05; OR&amp;gt;\u20057). The interaction between all polymorphisms and smoking were associated with CML development and IM resistance (P\u2005\u2264.04; OR&amp;gt;\u20053).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study results suggest the influence of SLC22A1 and SLCO1B3 polymorphisms and the interaction of smoking on CML development and IM response.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmab023","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T12:12:34Z","timestamp":1613823154000},"page":"584-596","source":"Crossref","is-referenced-by-count":9,"title":["Association of <i>SLC22A1<\/i>,<i>SLCO1B3<\/i> Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia"],"prefix":"10.1093","volume":"52","author":[{"given":"Fatemeh","family":"Mohammadi","sequence":"first","affiliation":[{"name":"Department of Biology, School of Science, Shahid Chamran University of Ahvaz , Ahvaz , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Golale","family":"Rostami","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran , Tehran , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dlnya","family":"Assad","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Science, Sulaimani University , Sulaymanyah , Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Shafiei","sequence":"additional","affiliation":[{"name":"Department of Biology, School of Science, Shahid Chamran University of Ahvaz , Ahvaz , Iran"},{"name":"Biotechnology and Biological Science Research Center, Shahid Chamran University of Ahvaz , Ahvaz , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-0713","authenticated-orcid":false,"given":"Mohammad","family":"Hamid","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran , Tehran , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Jalaeikhoo","sequence":"additional","affiliation":[{"name":"AJA Cancer Epidemiology Research and Treatment Center (AJA-CERTC), AJA University of Medical Sciences , Tehran , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"2023020507512009300_CIT0001","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/jhg.2015.11","article-title":"Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib","volume":"60","author":"Rostami","year":"2015","journal-title":"J Hum Genet"},{"key":"2023020507512009300_CIT0002","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"2023020507512009300_CIT0003","doi-asserted-by":"crossref","first-page":"e00717","DOI":"10.1002\/mgg3.717","article-title":"Influence of glutathione S-transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response","volume":"7","author":"Rostami","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"2023020507512009300_CIT0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.phrs.2018.02.005","article-title":"Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"131","author":"Cargnin","year":"2018","journal-title":"Pharmacol Res"},{"key":"2023020507512009300_CIT0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13046-017-0523-3","article-title":"Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment","volume":"36","author":"Jaruskova","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"2023020507512009300_CIT0006","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1479-7364-3-2-195","article-title":"Analysis and update of the human solute carrier (SLC) gene superfamily","volume":"3","author":"He","year":"2009","journal-title":"Hum Genomics"},{"key":"2023020507512009300_CIT0007","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2006","journal-title":"Blood"},{"key":"2023020507512009300_CIT0008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of \u03b11-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"2023020507512009300_CIT0009","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1248\/bpb.34.114","article-title":"Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia","volume":"34","author":"Nambu","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"2023020507512009300_CIT0010","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"2023020507512009300_CIT0011","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000336244","article-title":"Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients","volume":"127","author":"Zhong","year":"2012","journal-title":"Acta Haematol"},{"key":"2023020507512009300_CIT0012","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/tpj.2014.7","article-title":"The c. 480C&gt;G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia","volume":"14","author":"Di Paolo","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"2023020507512009300_CIT0013","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ejh.12235","article-title":"OCT 1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients","volume":"92","author":"Koren-Michowitz","year":"2014","journal-title":"Eur J Haematol"},{"key":"2023020507512009300_CIT0014","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1179\/1607845412Y.0000000067","article-title":"Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?","volume":"18","author":"Bedewy","year":"2013","journal-title":"Hematol"},{"key":"2023020507512009300_CIT0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.clpt.6100011","article-title":"Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics","volume":"81","author":"Smith","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2023020507512009300_CIT0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1179\/1607845414Y.0000000181","article-title":"Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients","volume":"20","author":"de Lima","year":"2015","journal-title":"Hematol"},{"key":"2023020507512009300_CIT0017","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tox.2016.07.011","article-title":"Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate","volume":"363","author":"Sayyed","year":"2016","journal-title":"Toxicology"},{"key":"2023020507512009300_CIT0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sj.bjc.6601487","article-title":"Cancer pharmacogenetics","volume":"90","author":"Marsh","year":"2004","journal-title":"Br J Cancer"},{"key":"2023020507512009300_CIT0019","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0145-2126(01)00048-0","article-title":"Smoking and acute myeloid leukemia: associations with morphology and karyotypic patterns and evaluation of dose\u2013response relations","volume":"25","author":"Bj\u00f6rk","year":"2001","journal-title":"Leuk Res"},{"key":"2023020507512009300_CIT0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/10428194.2011.625576","article-title":"Association of GSTT1 polymorphism with acute myeloid leukemia risk is dependent on smoking status","volume":"53","author":"Kim","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2023020507512009300_CIT0021","first-page":"42","article-title":"WHO 2016 definition of chronic myeloid leukemia and tyrosine kinase inhibitors","volume":"37","author":"Haznedaro\u011flu","year":"2020","journal-title":"Turk J Haematol"},{"key":"2023020507512009300_CIT0022","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023020507512009300_CIT0023","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"2023020507512009300_CIT0024","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"key":"2023020507512009300_CIT0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/newbio232031a0","article-title":"New technique for distinguishing between human chromosomes","volume":"232","author":"Sumner","year":"1971","journal-title":"Nature New Biology"},{"key":"2023020507512009300_CIT0026","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"2023020507512009300_CIT0027","first-page":"1727","article-title":"Effect of age and sex under imatinib mesylate therapy on chronic myeloid leukaemia patients: a pilot study from India","volume":"8","author":"Singh","year":"2017","journal-title":"Int J Pharm Sci Res"},{"key":"2023020507512009300_CIT0028","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2019.04.011","article-title":"First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: age and dose still matter","volume":"81","author":"Belohlavkova","year":"2019","journal-title":"Leuk Res"},{"key":"2023020507512009300_CIT0029","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/leu.2015.170","article-title":"OCT1 and imatinib transport in CML: is it clinically relevant?","volume":"29","author":"Watkins","year":"2015","journal-title":"Leukemia."},{"key":"2023020507512009300_CIT0030","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s12041-018-0978-9","article-title":"Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients","volume":"97","author":"Makhtar","year":"2018","journal-title":"J Genet"},{"key":"2023020507512009300_CIT0031","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2015.08.034","article-title":"Genetic variations of hOCT1 gene and CYP3A4\/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia","volume":"765","author":"Vaidya","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"2023020507512009300_CIT0032","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J Hum Genet"},{"key":"2023020507512009300_CIT0033","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","article-title":"Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia","volume":"35","author":"Maffioli","year":"2011","journal-title":"Leuk Res"},{"key":"2023020507512009300_CIT0034","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/leu.2010.188","article-title":"OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1","volume":"24","author":"White","year":"2010","journal-title":"Leukemia"},{"key":"2023020507512009300_CIT0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/0971-6866.92094","article-title":"Genetic analysis of OCT1 gene polymorphisms in an Indian population","volume":"17","author":"Umamaheswaran","year":"2011","journal-title":"Indian J Hum Genet"},{"key":"2023020507512009300_CIT0036","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3892\/or.2012.2153","article-title":"Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib","volume":"29","author":"Gromicho","year":"2013","journal-title":"Oncol Rep"},{"key":"2023020507512009300_CIT0037","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.5114\/aoms.2018.73538","article-title":"The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients","volume":"14","author":"Belohlavkova","year":"2018","journal-title":"Arch Med Sci"},{"key":"2023020507512009300_CIT0038","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2023020507512009300_CIT0039","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.mgene.2016.11.002","article-title":"Association of genetic polymorphisms of the ABCG2, ABCB1, SLCO1B3 genes and the response to imatinib in chronic myeloid leukemia patients with chronic phase","volume":"11","author":"Nair","year":"2017","journal-title":"Meta Gene"},{"key":"2023020507512009300_CIT0040","first-page":"244","article-title":"Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia","volume":"33","author":"Yamakawa","year":"2011","journal-title":"Ther Drug Monit"},{"key":"2023020507512009300_CIT0041","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/pgs-2018-0139","article-title":"Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia","volume":"20","author":"Wang","year":"2019","journal-title":"Pharmacogenomics"},{"key":"2023020507512009300_CIT0042","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.leukres.2019.05.012","article-title":"Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients","volume":"82","author":"Vasconcelos","year":"2019","journal-title":"Leuk Res"},{"key":"2023020507512009300_CIT0043","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/cncr.30636","article-title":"Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death","volume":"123","author":"Lauseker","year":"2017","journal-title":"Cancer"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/52\/6\/584\/49091791\/lmab023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/52\/6\/584\/49091791\/lmab023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T07:51:57Z","timestamp":1675583517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/52\/6\/584\/6299328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,15]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmab023","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,6,15]]}}}